دورية أكاديمية
أعرض في EDS

A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.

التفاصيل البيبلوغرافية
العنوان: A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.
المؤلفون: Li C; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA., Anderson AK; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA., Ruminski P; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Rettig M; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Karpova D; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Kiem HP; Stem and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA., DiPersio JF; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Lieber A; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA.
المصدر: Blood advances [Blood Adv] 2024 Aug 13; Vol. 8 (15), pp. 4089-4101.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Society of Hematology, [2016]-
مواضيع طبية MeSH: Anemia, Sickle Cell*/therapy , Anemia, Sickle Cell*/genetics , Genetic Therapy*/methods , Granulocyte Colony-Stimulating Factor*/pharmacology , Hematopoietic Stem Cell Mobilization*/methods, Animals ; Humans ; Mice ; Benzylamines ; Cyclams/pharmacology ; Cyclams/therapeutic use ; Disease Models, Animal ; Gene Editing ; Hematopoietic Stem Cell Transplantation/methods ; Hematopoietic Stem Cells/metabolism ; Heterocyclic Compounds/pharmacology ; Heterocyclic Compounds/therapeutic use
مستخلص: Abstract: We have reported the direct repair of the sickle cell mutation in vivo in a disease model using vectorized prime editors after hematopoietic stem cell (HSC) mobilization with granulocyte colony-stimulating factor (G-CSF)/AMD3100. The use of G-CSF for HSC mobilization is a hurdle for the clinical translation of this approach. Here, we tested a G-CSF-free mobilization regimen using WU-106, an inhibitor of integrin α4β1, plus AMD3100 for in vivo HSC prime editing in sickle cell disease (SCD) mice. Mobilization with WU-106 + AMD3100 in SCD mice was rapid and efficient. In contrast to the G-CSF/AMD3100 approach, mobilization of activated granulocytes and elevation of the key proinflammatory cytokine interleukin-6 in the serum were minimal. The combination of WU-106 + AMD3100 mobilization and IV injection of the prime editing vector together with in vivo selection resulted in ∼23% correction of the SCD mutation in the bone marrow and peripheral blood cells of SCD mice. The treated mice demonstrated phenotypic correction, as reflected by normalized blood parameters and spleen size. Editing frequencies were significantly increased (29%) in secondary recipients, indicating the preferential mobilization/transduction of long-term repopulating HSCs. Using this approach, we found <1% undesired insertions/deletions and no detectable off-target editing at the top-scored potential sites. Our study shows that in vivo transduction to treat SCD can now be done within 2 hours involving only simple IV injections with a good safety profile. The same-day mobilization regimen makes in vivo HSC gene therapy more attractive for resource-poor settings, where SCD does the most damage.
(© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
References: Blood Adv. 2022 Aug 9;6(15):4360-4372. (PMID: 35679480)
FEBS Lett. 2019 Dec;593(24):3461-3483. (PMID: 31769012)
Bone Marrow Transplant. 2008 Feb;41(4):331-8. (PMID: 17994119)
Haematologica. 2020 Jan;105(1):71-82. (PMID: 31073070)
Blood. 2021 Nov 25;138(21):2148-2152. (PMID: 34521115)
Cytotherapy. 2009;11(4):464-71. (PMID: 19513902)
Clin Exp Immunol. 2001 May;124(2):180-9. (PMID: 11422193)
Blood Adv. 2024 Mar 26;8(6):1379-1383. (PMID: 38190608)
Blood. 2023 Apr 27;141(17):2085-2099. (PMID: 36800642)
Leukemia. 2012 Jan;26(1):34-53. (PMID: 21886173)
Blood. 2016 Nov 3;128(18):2206-2217. (PMID: 27554082)
Thromb Haemost. 2011 Apr;105(4):655-62. (PMID: 21301783)
Blood. 2005 Sep 1;106(5):1867-74. (PMID: 15890685)
JCI Insight. 2020 Aug 20;5(16):. (PMID: 32814708)
J Clin Invest. 2019 May 14;129(7):2745-2759. (PMID: 31085833)
Mol Ther. 2024 Jan 3;32(1):103-123. (PMID: 37919899)
Blood. 2020 Apr 2;135(14):1185-1188. (PMID: 32062672)
Bioinformatics. 2014 May 15;30(10):1473-5. (PMID: 24463181)
FEBS Lett. 2019 Dec;593(24):3623-3648. (PMID: 31705806)
Nat Methods. 2017 Jun;14(6):607-614. (PMID: 28459458)
Br Med Bull. 2023 Sep 12;147(1):108-120. (PMID: 37460391)
Mol Ther. 2021 Feb 3;29(2):822-837. (PMID: 32949495)
Blood Adv. 2021 Mar 9;5(5):1239-1249. (PMID: 33646305)
Viruses. 2022 Apr 24;14(5):. (PMID: 35632630)
Mol Ther Methods Clin Dev. 2021 Dec 06;24:127-141. (PMID: 35036470)
Cell. 2022 Jun 23;185(13):2248-2264.e21. (PMID: 35617958)
معلومات مُعتمدة: INV-038139 United States GATES Bill & Melinda Gates Foundation; R01 HL141781 United States HL NHLBI NIH HHS; R35 CA210084 United States CA NCI NIH HHS; R50 CA211466 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Benzylamines)
0 (Cyclams)
143011-72-7 (Granulocyte Colony-Stimulating Factor)
0 (Heterocyclic Compounds)
S915P5499N (plerixafor)
تواريخ الأحداث: Date Created: 20240606 Date Completed: 20240731 Latest Revision: 20240830
رمز التحديث: 20240830
مُعرف محوري في PubMed: PMC11342186
DOI: 10.1182/bloodadvances.2024012757
PMID: 38843380
قاعدة البيانات: MEDLINE
الوصف
تدمد:2473-9537
DOI:10.1182/bloodadvances.2024012757